Metaphore Pharmaceuticals

ThyroChek is the only available rapid test for elevated TSH approved by the FDA. It is a rapid, qualitative test for elevated TSH, thyroid stimulating hormone, a clinical indicator of hypothyroidism. Screening Devices Canada is producing products for the thyroid health market in the United States which is a market valued at $1.2B annually.

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Keystone Nano seeks to improve human health by creating new ways to diagnose and treat human diseases and improve the quality of life. Keystone Nano partners with healthcare companies to the development and speed the market launch of nano-enabled therapeutics to seek/treat/image a variety of conditions.

InnoZen, Inc. discovers, develops, and markets, or out licenses, over-the-counter (OTC) health products that fulfill unmet consumer need. InnoZen developed a oral strip to deliver drug active ingredients. This technology is currently being used in new Chloraseptic' Relief Strips' and has many potential applications in both the human and veterinary markets.

Palkion, Inc. is a private early stage company developing oral drugs to treat anemia based on the discovery and development of compounds that inhibit prolyl hydroxylase enzymes.

Stemina Cell Discovery discovers and validates small molecules as biomarkers for high-throughput drug screening and disease diagnostics using an all human system comprised of stem cells and the company's metabolomics platform. Metabolomics aims to enable the discovery of small molecules that can be used as candidate biomarkers of disease and pharmacological efficacy or toxicity. The human embryonic stem cell metabolome is a source of candidate biomarkers to predict, diagnose or measure the progress of disease or toxic response. Stemina aims to provide compound screening and diagnostic development for the pharmaceutical and biotechnology industries and academia under contract services or joint discovery agreements.